Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 4/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404170 | 0.88 | TP53 (0.64) | RIOK2MAPK10GSK3AL3MBTL1TP53 | |
| SCHEMBL26805734 | 0.87 | L3MBTL1 (0.49) | RIOK2MAPK10GSK3AL3MBTL1PIK3C3 | |
| SCHEMBL25189182 | 0.86 | RIOK2 (0.60) | RIOK2MAPK10GSK3AL3MBTL1TP53 | |
| SCHEMBL25402019 | 0.85 | NR3C2 (0.67) | RIOK2MAPK10GSK3AL3MBTL1TP53 | |
| SCHEMBL22281654 | 0.84 | RIOK2 (0.62) | RIOK2MAPK10GSK3AL3MBTL1TP53 | |
| SCHEMBL30518614 | 0.83 | AAK1 (0.49) | RIOK2L3MBTL1PIK3C3ALDH1A1GCK | |
| SCHEMBL6586141 | 0.83 | GCK (0.50) | RIOK2L3MBTL1PIK3C3GCK | |
| SCHEMBL25516915 | 0.83 | RIOK2 (0.48) | RIOK2MAPK10GSK3ATP53NR3C2 | |
| SCHEMBL14872565 | 0.83 | NPC1 (0.55) | L3MBTL1PIK3C3ADORA3SMN1; SMN2GCK | |
| SCHEMBL23988961 | 0.82 | L3MBTL1 (0.47) | L3MBTL1PIK3C3GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-3402785-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-21 | — | — | EP | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| WO-2017121649-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| CN-1918127-B | New cyclocompound having 4-pyridylalkylthio group to which substituted or unsubstituted amino group is introduced | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2012-02-15 | — | — | CN | disclosed |
| EP-2044037-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| CN-1918127-A | New cyclocompound having 4-pyridylalkylthio group to which sustituted or unsubstituted amino group is introduced | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RIOK2 2619/4885MAPK10 1498/4885GSK3A 3009/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | RIOK2 2209/4885MAPK10 3933/4885GSK3A 580/4885 |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | RIOK2 2555/4885MAPK10 2739/4885GSK3A 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.